Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Lessons Learned from Two Scleroderma Lung Studies (Plus a Third That’s Recruiting Sites)

Elizabeth R. Volkmann, MD, MS, Michael D. Roth, MD, Donald P. Tashkin, MD, Cathie Spino, ScD, & Dinesh Khanna, MD, MS  |  Issue: August 2019  |  

References

  1. Volkmann ER, Tashkin DP. Treatment of systemic sclerosis-related interstitial lung disease: A review of existing and emerging therapies. Ann Am Thorac Soc. 2016 Nov;13:2045–2056.
  2. Au K, Khanna D, Clements PJ, et al. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: Lessons from clinical trials. Curr Rheumatol Rep. 2009 Apr;11(2):111–119.
  3. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006 Jun 22;354(25):2655–2666.
  4. Kim HJ, Brown M, Elashoff F, et al. Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol. 2011;21(12):2455–2465.
  5. Tashkin DP, Elashoff R, Clements PJ, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007 Nov 15;176(10):1026–1034.
  6. Tashkin DP, Roth MD, Clements PJ, et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease: Scleroderma lung study II (SLS-II), a double-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2016 Sep;4(9):708–719.
  7. Volkmann ER, Tashkin DP, Li N, et al. Mycophenolate versus placebo for patients with systemic sclerosis-related interstitial lung disease. Arthritis Rheumatol. 2017 Jul;69(7):1451–1460.
  8. Volkmann ER, Tashkin DP, Sim M, et al. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts. Ann Rheum Dis. 2019 Jan;78(1):122–130.
  9. Khanna D, Albera C, Fischer A, et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: The LOTUSS trial. J Rheumatol. 2016 Sep;43(9):1672–1679.
  10. Distler O, Brown KK, Distler JHW, et al. Design of a randomized, placebo-controlled clinical trial of nintedanib in patients with systemic sclerosis-associated interstitial lung disease (SENCSCIS). Clin Exp Rheumatol. 2017 Sep–Oct;35 Suppl 106(4):75–81.

Related Articles